B-intervention	0	8	Thoracic
I-intervention	9	22	paravertebral
I-intervention	23	31	regional
I-intervention	32	42	anesthesia
O	43	46	for
B-condition	47	51	pain
I-condition	52	58	relief
O	59	61	in
B-eligibility	62	70	patients
I-eligibility	71	75	with
I-eligibility	76	82	breast
I-eligibility	83	89	cancer
I-eligibility	90	97	surgery
O	97	98	.

O	99	102	The
O	103	110	present
O	111	116	study
O	117	122	aimed
O	123	125	to
O	126	132	assess
O	133	136	the
O	137	145	efficacy
O	146	149	and
O	150	156	safety
O	157	159	of
O	160	168	thoracic
O	169	182	paravertebral
O	183	191	regional
O	192	202	anesthesia
O	203	204	(
O	204	210	TPVBRA
O	210	211	)
O	212	214	in
O	215	223	patients
O	224	228	with
O	229	235	breast
O	236	242	cancer
O	243	250	surgery
O	250	251	.

O	252	254	In
O	255	260	total
O	260	261	,
B-total-participants	262	264	72
O	265	273	patients
O	274	284	undergoing
O	285	291	breast
O	292	298	cancer
O	299	306	surgery
O	307	311	were
O	312	320	randomly
O	321	328	divided
O	329	333	into
O	334	336	an
O	337	349	intervention
O	350	355	group
O	356	359	and
O	360	361	a
B-control	362	369	control
I-control	370	375	group
O	375	376	;
O	377	381	each
O	382	387	group
O	388	397	contained
B-intervention-participants	398	400	36
O	401	409	subjects
O	409	410	.

O	411	415	Both
O	416	422	groups
O	423	431	received
O	432	438	TPVBRA
O	439	443	with
O	444	446	20
O	447	449	mL
O	450	451	0
O	451	452	.
O	452	454	25
O	454	455	%
O	456	467	bupivacaine
O	467	468	.

O	469	471	In
O	472	480	addition
O	480	481	,
O	482	490	subjects
O	491	493	in
O	494	497	the
O	498	510	intervention
O	511	516	group
O	517	521	also
O	522	530	received
O	531	533	an
O	534	544	additional
O	545	546	1
O	547	548	Î¼
O	548	549	g
O	549	550	/
O	550	552	kg
O	553	568	dexmedetomidine
O	568	569	.

O	570	575	Heart
O	576	580	rate
O	581	582	(
O	582	584	HR
O	584	585	)
O	585	586	,
O	587	595	systolic
O	596	601	blood
O	602	610	pressure
O	611	612	(
O	612	615	SBP
O	615	616	)
O	616	617	,
O	618	627	diastolic
O	628	633	blood
O	634	642	pressure
O	643	644	(
O	644	647	DBP
O	647	648	)
O	648	649	,
O	650	654	pain
O	655	664	intensity
O	665	666	(
O	666	674	measured
O	675	677	by
O	678	684	visual
O	685	693	analogue
O	694	699	scale
O	699	700	,
O	701	704	VAS
O	704	705	)
O	705	706	,
O	707	710	and
O	711	720	analgesic
O	721	732	consumption
O	733	737	were
O	738	746	assessed
O	746	747	;
O	748	755	adverse
O	756	762	events
O	763	767	were
O	768	772	also
O	773	781	recorded
O	781	782	.

O	783	794	Significant
O	795	806	differences
O	807	811	were
O	812	820	observed
O	821	823	in
O	824	826	HR
O	827	828	(
O	828	829	P
O	830	831	<
O	832	833	.
O	833	835	05
O	835	836	)
O	836	837	,
O	838	841	SBP
O	842	843	(
O	843	844	P
O	845	846	<
O	847	848	.
O	848	850	05
O	850	851	)
O	851	852	,
O	853	856	and
B-outcome	857	860	DBP
O	861	862	(
O	862	863	P
O	864	865	<
O	866	867	.
O	867	869	05
O	869	870	)
O	871	873	at
O	874	877	the
O	878	880	30
O	880	881	-
O	881	887	minute
O	888	893	point
O	894	900	during
O	901	908	surgery
O	909	916	between
O	917	920	the
O	921	922	2
O	923	929	groups
O	929	930	.

O	931	933	In
O	934	942	addition
O	942	943	,
O	944	947	the
O	948	952	time
O	953	955	of
O	956	959	the
O	960	965	first
O	966	980	administration
O	981	983	of
O	984	993	analgesia
O	994	995	(
O	995	996	P
O	997	998	=
O	999	1000	.
O	1000	1003	043
O	1003	1004	)
O	1005	1008	and
O	1009	1012	the
B-outcome	1013	1017	mean
I-outcome	1018	1029	consumption
I-outcome	1030	1032	of
I-outcome	1033	1042	analgesic
I-outcome	1043	1049	agents
O	1050	1051	(
O	1051	1052	P
O	1053	1054	=
O	1055	1056	.
O	1056	1059	035
O	1059	1060	)
O	1061	1063	in
O	1064	1067	the
O	1068	1080	intervention
O	1081	1086	group
O	1087	1091	were
O	1092	1096	much
O	1097	1103	better
O	1104	1108	than
O	1109	1114	those
O	1115	1117	in
O	1118	1121	the
O	1122	1129	control
O	1130	1135	group
O	1135	1136	.

O	1137	1144	However
O	1144	1145	,
O	1146	1148	no
O	1149	1160	significant
O	1161	1172	differences
O	1173	1175	in
B-outcome	1176	1178	HR
I-outcome	1179	1181	or
I-outcome	1182	1185	VAS
O	1186	1190	were
O	1191	1196	found
O	1197	1199	at
O	1200	1203	any
O	1204	1208	time
O	1209	1214	point
O	1215	1220	after
O	1221	1228	surgery
O	1229	1230	(
O	1230	1231	P
O	1232	1233	>
O	1234	1235	.
O	1235	1237	05
O	1237	1238	)
O	1238	1239	.

O	1240	1251	Furthermore
O	1251	1252	,
O	1253	1260	similar
B-outcome	1261	1268	adverse
I-outcome	1269	1275	events
O	1276	1280	were
O	1281	1289	detected
O	1290	1292	in
O	1293	1297	both
O	1298	1304	groups
O	1305	1306	(
O	1306	1307	P
O	1308	1309	>
O	1310	1311	.
O	1311	1313	05
O	1313	1314	)
O	1314	1315	.

O	1316	1319	The
O	1320	1327	results
O	1328	1330	of
O	1331	1335	this
O	1336	1341	study
O	1342	1348	showed
O	1349	1353	that
O	1354	1360	TPVBRA
O	1361	1369	combined
O	1370	1374	with
O	1375	1386	bupivacaine
O	1387	1390	and
O	1391	1406	dexmedetomidine
O	1407	1410	can
O	1411	1418	enhance
O	1419	1422	the
O	1423	1431	duration
O	1432	1435	and
O	1436	1443	quality
O	1444	1446	of
O	1447	1456	analgesia
O	1457	1464	without
O	1465	1472	serious
O	1473	1480	adverse
O	1481	1487	events
O	1487	1488	.
